Subscribe
shutterstock_1878287359_mats-wiklund
Mats Wiklund / Shutterstock.com
24 February 2022Big Pharma

AstraZeneca sues Taro in blood-thinning drug patent dispute

AstraZeneca has sued  Taro Pharmaceuticals in two US federal courts alleging that Taro’s planned generic blood-thinning treatment infringes a patent for its  Brilinta (ticagrelor) medication.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
AstraZeneca prevails in GSK royalties row at UK High Court
6 April 2023   Feud involved a blockbuster cancer drug belonging to a family of PARP inhibitors | GSK unit failed to persuade the court of the merits of its ‘certain uses’ argument.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Americas
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Americas
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Big Pharma
AstraZeneca prevails in GSK royalties row at UK High Court
6 April 2023   Feud involved a blockbuster cancer drug belonging to a family of PARP inhibitors | GSK unit failed to persuade the court of the merits of its ‘certain uses’ argument.

More on this story

Big Pharma
AstraZeneca prevails in GSK royalties row at UK High Court
6 April 2023   Feud involved a blockbuster cancer drug belonging to a family of PARP inhibitors | GSK unit failed to persuade the court of the merits of its ‘certain uses’ argument.

More features

Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler
WilmerHale gains partner with ‘deep expertise’
Bayer, Orion take on Indian generic over $117bn drug
‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court